Institute of Medical Genetics and Applied Genomics, University of Tübingen, 72076, Tübingen, Germany; Department of Neuropediatrics, Developmental Neurology and Social Pediatrics, University of Tübingen, 72076, Tübingen, Germany.
Institute of Medical Genetics and Applied Genomics, University of Tübingen, 72076, Tübingen, Germany.
Eur J Med Genet. 2020 Jul;63(7):103938. doi: 10.1016/j.ejmg.2020.103938. Epub 2020 Apr 28.
Pontocerebellar hypoplasia (PCH) comprises a clinically and genetically heterogeneous group of disorders characterized by hypoplasia and degeneration of the cerebellum and ventral pons. To date at least 18 different clinical subtypes of PCH associated with pathogenic variants in 19 different genes have been described. Only recently, bi-allelic variants in TBC1D23 have been reported as the underlying molecular defect in seven index cases with a suspected non-degenerative form of PCH, PCH type 11 (PCH11). We used exome sequencing to investigate an individual with global developmental delay, ataxia, seizures, and progressive PCH. Brain volume was evaluated over a disease course of 14 years using volumetric magnetic resonance imaging (MRI). Volume alterations were compared to age-matched controls as well as data from children with PCH2. We identified a homozygous frameshift variant in exon 9 of 18 of TBC1D23 predicting a loss of protein function. Brain morphometry revealed a pattern of pontine, brain stem, and supratentorial volume loss similar to PCH2 patients although less pronounced. Intriguingly, cerebral MRI findings at the age of 1 and 15 years clearly showed progressive atrophy of the cerebellum, especially the hemispheres. In four of the cases reported in the literature cerebellar hemispheres could be evaluated on the MRIs displayed, they also showed atrophic foliae. While pontine hypoplasia and pronounced microcephaly are in line with previous reports on PCH11, our observations of clearly postnatal atrophy of the cerebellum argues for a different pathomechanism than in the other forms of PCH and supports the hypothesis that TBC1D23 deficiency predominantly interferes with postnatal rather than with prenatal cerebellar development.
桥小脑发育不良(PCH)是一组临床表现和遗传异质性的疾病,其特征为小脑和腹侧脑桥发育不良和退行性变。迄今为止,至少已有 18 种不同的 PCH 临床亚型与 19 种不同基因的致病性变异相关。最近才报道了双等位基因 TBC1D23 变异是 7 例疑似非退行性 PCH(PCH11)的潜在分子缺陷。我们使用外显子组测序来研究一名患有全面发育迟缓、共济失调、癫痫发作和进行性 PCH 的个体。使用容积磁共振成像(MRI)在 14 年的疾病过程中评估脑容量。将体积变化与年龄匹配的对照组以及 PCH2 患儿的数据进行比较。我们在 18 号 TBC1D23 外显子 9 中发现了一个纯合移码变异,预测该蛋白功能丧失。脑形态计量学显示桥脑、脑干和大脑半球的体积丢失模式与 PCH2 患者相似,尽管程度较轻。有趣的是,在 1 岁和 15 岁时的脑 MRI 结果清楚地显示出小脑,尤其是半球的进行性萎缩。在文献中报道的 4 例病例中,可对 MRI 上显示的小脑半球进行评估,也显示出萎缩的叶。虽然桥脑发育不良和明显的小头与以前关于 PCH11 的报告一致,但我们对小脑在出生后明显萎缩的观察结果表明,其发病机制与其他类型的 PCH 不同,并支持 TBC1D23 缺乏主要干扰出生后而不是产前小脑发育的假说。